ABION has reached its upper limit following the announcement of its U.S. patent registration for core technology related to its next-generation immune-oncology platform.
According to the Korea Exchange, as of 2:49 PM on August 10, ABION's stock was trading at 841 won, up 194 won (29.98%) from the previous trading day.
Earlier in the day, ABION announced that it had completed the U.S. patent registration for its next-generation immune-oncology platform, the Interferon Beta Antibody Conjugate (iRAC™).
This patent covers a recombinant protein technology that fuses a mutant form of interferon-beta (IFN-β Mutein) developed independently by ABION with an antibody targeting cancer cells. The company stated that this patent comprehensively protects the core structure of the iRAC™ platform.
iRAC™ is a platform technology designed to selectively deliver interferon-beta to the tumor microenvironment using tumor-targeting antibodies. It aims to enhance anti-tumor effects by inducing superior therapeutic persistence and immune activity compared to existing antibody-drug conjugate (ADC) therapies.
An ABION representative remarked, "This U.S. patent is significant as it protects the core technology of the iRAC™ platform rather than a specific candidate substance. By securing the platform's scalability and exclusive rights, we have laid the groundwork for more aggressive global commercialization and technology transfer strategies."
Meanwhile, ABION is a KOSDAQ-listed biotechnology company focused on researching and developing biomarker-based precision functional anti-cancer drugs and next-generation immune-oncology platforms.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.